<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34675267</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Characteristics of serum metabolites in sporadic amyotrophic lateral sclerosis patients based on gas chromatography-mass spectrometry.</ArticleTitle><Pagination><StartPage>20786</StartPage><MedlinePgn>20786</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">20786</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-00312-8</ELocationID><Abstract><AbstractText>To identify differential metabolites and metabolic pathways and provide guidance for the novel biomarkers for diagnosis and prognosis of amyotrophic lateral sclerosis (ALS). ALS patients and people without nervous diseases were recruited. Metabolomic analysis was performed using gas chromatography-mass spectrometry (GC/MS). The orthogonal projections to latent structures discriminant analysis (OPLS-DA) were used to identify differential metabolites. Kyoto Encyclopedia of Genes and Genomes and MetaboAnalyst were used to identify metabolic pathways. 75 metabolites were detected and aligned. The OPLS-DA showed the metabolomic profile of ALS patients and those in the fast-progression and slow-progression ALS groups differed from that of CTRL (p&#x2009;&lt;&#x2009;0.05). The levels of maltose, glyceric acid, lactic acid, beta-alanine, phosphoric acid, glutamic acid, ethanolamine and glycine in ALS were significantly higher, while 2,4,6-tri-tert-butylbenzenethiol was lower. Glycine, serine and threonine metabolism, D-glutamine and D-glutamate metabolism, alanine, aspartate, and glutamate metabolism, beta-alanine metabolism, and pyruvate metabolism were significantly altered metabolic pathways in ALS. ROC was used to discriminate ALS from CTRL with an AUC of 0.898 (p&#x2009;&lt;&#x2009;0.001) using 2,4,6-tri-tert-butylbenzenethiol, beta-alanine, glycine, and ethanolamine. The serum metabolites and metabolic pathways in ALS patients are significantly altered compared with CTRL. These findings may contribute to the early diagnosis of ALS.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital, Xi'an Jiaotong University, 277 Western Yanta Rd, Xi'an, 710061, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Qiaoyi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and Genetics, Xian Jiaotong University Health Science Center, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Qingqing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital, Xi'an Jiaotong University, 277 Western Yanta Rd, Xi'an, 710061, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ronghua</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital, Xi'an Jiaotong University, 277 Western Yanta Rd, Xi'an, 710061, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Jiaoting</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital, Xi'an Jiaotong University, 277 Western Yanta Rd, Xi'an, 710061, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Fangfang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital, Xi'an Jiaotong University, 277 Western Yanta Rd, Xi'an, 710061, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital, Xi'an Jiaotong University, 277 Western Yanta Rd, Xi'an, 710061, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital, Xi'an Jiaotong University, 277 Western Yanta Rd, Xi'an, 710061, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital, Xi'an Jiaotong University, 277 Western Yanta Rd, Xi'an, 710061, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Songzhen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital, Xi'an Jiaotong University, 277 Western Yanta Rd, Xi'an, 710061, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dang</LastName><ForeName>Yonghui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Key Laboratory of Environment and Genes Related to Diseases of the Education Ministry, Key Laboratory of the Health Ministry for Forensic Medicine, College of Medicine and Forensics, Xi'an Jiaotong University Health Science Center, Xi'an, China. psydyh@mail.xjtu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dang</LastName><ForeName>Jingxia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital, Xi'an Jiaotong University, 277 Western Yanta Rd, Xi'an, 710061, China. jxdang2000@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008401" MajorTopicYN="N">Gas Chromatography-Mass Spectrometry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055432" MajorTopicYN="N">Metabolomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34675267</ArticleId><ArticleId IdType="pmc">PMC8531355</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-00312-8</ArticleId><ArticleId IdType="pii">10.1038/s41598-021-00312-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Es MA, et al. Amyotrophic lateral sclerosis. The Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/s0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Gualano MR, et al. New ways to promote public health: Lessons from the international ice bucket challenge. Public Health. 2016;140:276&#x2013;277. doi: 10.1016/j.puhe.2016.05.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.puhe.2016.05.026</ArticleId><ArticleId IdType="pubmed">27377474</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, et al. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, et al. Incidence of amyotrophic lateral sclerosis in Europe. J. Neurol. Neurosurg. Psychiatry. 2010;81:385&#x2013;390. doi: 10.1136/jnnp.2009.183525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.183525</ArticleId><ArticleId IdType="pmc">PMC2850819</ArticleId><ArticleId IdType="pubmed">19710046</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayaux J, et al. Survival of amyotrophic lateral sclerosis patients after admission to the intensive care unit for acute respiratory failure: An observational cohort study. J. Crit. Care. 2019;50:54&#x2013;58. doi: 10.1016/j.jcrc.2018.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2018.11.007</ArticleId><ArticleId IdType="pubmed">30472526</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan S, Orrell RW. Pathogenesis of amyotrophic lateral sclerosis. Br. Med. Bull. 2016;119:87&#x2013;98. doi: 10.1093/bmb/ldw026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bmb/ldw026</ArticleId><ArticleId IdType="pubmed">27450455</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst. Rev. 2012 doi: 10.1002/14651858.CD001447.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001447.pub3</ArticleId><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jongh AD, van Eijk RPA, van den Berg LH. Evidence for a multimodal effect of riluzole in patients with ALS? J. Neurol. Neurosurg. Psychiatry. 2019 doi: 10.1136/jnnp-2018-320211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-320211</ArticleId><ArticleId IdType="pubmed">30846539</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q, et al. Unique characteristics of the genetics epidemiology of amyotrophic lateral sclerosis in China. Sci. China Life Sci. 2019;62:517&#x2013;525. doi: 10.1007/s11427-018-9453-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11427-018-9453-x</ArticleId><ArticleId IdType="pubmed">30863961</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR. Mutations in Cu/Zn superoxide-dismutase gene are associated with familial amyotrophic-lateral-sclerosis (Vol 362, Pg 59, 1993) Nature. 1993;364:362&#x2013;362. doi: 10.1038/364362c0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/364362c0</ArticleId><ArticleId IdType="pubmed">8332197</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis S, Goizet C, Soulages A, Vallat JM, Masson GL. Genetics of amyotrophic lateral sclerosis: A review. J. Neurol. Sci. 2019;399:217&#x2013;226. doi: 10.1016/j.jns.2019.02.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.02.030</ArticleId><ArticleId IdType="pubmed">30870681</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 2014;17:17&#x2013;23. doi: 10.1038/nn.3584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3584</ArticleId><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Gugliandolo A, Giacoppo S, Bramanti P, Mazzon E. NLRP3 inflammasome activation in a transgenic amyotrophic lateral sclerosis model. Inflammation. 2018;41:93&#x2013;103. doi: 10.1007/s10753-017-0667-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-017-0667-5</ArticleId><ArticleId IdType="pubmed">28936769</ArticleId></ArticleIdList></Reference><Reference><Citation>Qureshi IA, Mehler MF. Advances in epigenetics and epigenomics for neurodegenerative diseases. Curr. Neurol. Neurosci. Rep. 2011;11:464&#x2013;473. doi: 10.1007/s11910-011-0210-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-011-0210-2</ArticleId><ArticleId IdType="pmc">PMC4461866</ArticleId><ArticleId IdType="pubmed">21671162</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Hardiman O. The epidemiology of ALS: A conspiracy of genes, environment and time. Nat. Rev. Neurol. 2013;9:617&#x2013;628. doi: 10.1038/nrneurol.2013.203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Paez-Colasante X, Figueroa-Romero C, Sakowski SA, Goutman SA, Feldman EL. Amyotrophic lateral sclerosis: Mechanisms and therapeutics in the epigenomic era. Nat. Rev. Neurol. 2015;11:266&#x2013;279. doi: 10.1038/nrneurol.2015.57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.57</ArticleId><ArticleId IdType="pubmed">25896087</ArticleId></ArticleIdList></Reference><Reference><Citation>Kori M, Aydin B, Unal S, Arga KY, Kazan D. Metabolic biomarkers and neurodegeneration: A pathway enrichment analysis of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. OMICS. 2016;20:645&#x2013;661. doi: 10.1089/omi.2016.0106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/omi.2016.0106</ArticleId><ArticleId IdType="pubmed">27828769</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinones MP, Kaddurah-Daouk R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol. Dis. 2009;35:165&#x2013;176. doi: 10.1016/j.nbd.2009.02.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2009.02.019</ArticleId><ArticleId IdType="pubmed">19303440</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, Tan HY, Wang N, Wang X, Feng Y. Deciphering hepatocellular carcinoma through metabolomics: From biomarker discovery to therapy evaluation. Cancer Manag. Res. 2018;10:715&#x2013;734. doi: 10.2147/CMAR.S156837.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CMAR.S156837</ArticleId><ArticleId IdType="pmc">PMC5903488</ArticleId><ArticleId IdType="pubmed">29692630</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C, Guo ZG, He B, Yao WZ. Metabolic alterations in the sera of Chinese patients with mild persistent asthma: A GC-MS-based metabolomics analysis. Acta Pharmacol. Sin. 2015;36:1356&#x2013;1366. doi: 10.1038/aps.2015.102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/aps.2015.102</ArticleId><ArticleId IdType="pmc">PMC4635323</ArticleId><ArticleId IdType="pubmed">26526201</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatano T, Saiki S, Okuzumi A, Mohney RP, Hattori N. Identification of novel biomarkers for Parkinson's disease by metabolomic technologies. J. Neurol. Neurosurg. Psychiatry. 2016;87:295&#x2013;301. doi: 10.1136/jnnp-2014-309676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-309676</ArticleId><ArticleId IdType="pubmed">25795009</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharaoh G, et al. Metabolic and stress response changes precede disease onset in the spinal cord of mutant SOD1 ALS mice. Front. Neurosci. 2019;13:487. doi: 10.3389/fnins.2019.00487.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00487</ArticleId><ArticleId IdType="pmc">PMC6554287</ArticleId><ArticleId IdType="pubmed">31213966</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortelli R, et al. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: A possible marker of disease severity and progression. Eur. J. Neurol. 2012;19:1561&#x2013;1567. doi: 10.1111/j.1468-1331.2012.03777.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2012.03777.x</ArticleId><ArticleId IdType="pubmed">22680408</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J, et al. Comprehensive metabolomics identified lipid peroxidation as a prominent feature in human plasma of patients with coronary heart diseases. Redox Biol. 2017;12:899&#x2013;907. doi: 10.1016/j.redox.2017.04.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2017.04.032</ArticleId><ArticleId IdType="pmc">PMC5415551</ArticleId><ArticleId IdType="pubmed">28472752</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton KA, et al. Biochemical alterations associated with ALS. Amyotroph. Lateral Scler. 2012;13:110&#x2013;118. doi: 10.3109/17482968.2011.619197.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2011.619197</ArticleId><ArticleId IdType="pubmed">22117131</ArticleId></ArticleIdList></Reference><Reference><Citation>Cieslarova Z, Lopes FS, do Lago CL, Fred MC, Jr, Colnaghi Simionato AV. Capillary electrophoresis tandem mass spectrometry determination of glutamic acid and homocysteine's metabolites: Potential biomarkers of amyotrophic lateral sclerosis. Talanta. 2017;170:63&#x2013;68. doi: 10.1016/j.talanta.2017.03.103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.talanta.2017.03.103</ArticleId><ArticleId IdType="pubmed">28501214</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, et al. Differences in metabolite profile between blood plasma and serum. Anal. Biochem. 2010;406:105&#x2013;112. doi: 10.1016/j.ab.2010.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ab.2010.07.015</ArticleId><ArticleId IdType="pubmed">20655863</ArticleId></ArticleIdList></Reference><Reference><Citation>Madji Hounoum B, et al. The metabolic disturbances of motoneurons exposed to glutamate. Mol. Neurobiol. 2018;55:7669&#x2013;7676. doi: 10.1007/s12035-018-0945-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-0945-8</ArticleId><ArticleId IdType="pubmed">29435916</ArticleId></ArticleIdList></Reference><Reference><Citation>King AE, Woodhouse A, Kirkcaldie MT, Vickers JC. Excitotoxicity in ALS: Overstimulation, or overreaction? Exp. Neurol. 2016;275(Pt 1):162&#x2013;171. doi: 10.1016/j.expneurol.2015.09.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2015.09.019</ArticleId><ArticleId IdType="pubmed">26584004</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonansco C, et al. Glutamate released spontaneously from astrocytes sets the threshold for synaptic plasticity. Eur. J. Neurosci. 2011;33:1483&#x2013;1492. doi: 10.1111/j.1460-9568.2011.07631.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2011.07631.x</ArticleId><ArticleId IdType="pubmed">21395864</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, Mavel S, Corcia P, Gordon PH. The glutamate hypothesis in ALS: Pathophysiology and drug development. Curr. Med. Chem. 2014;21:3551&#x2013;3575. doi: 10.2174/0929867321666140916120118.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867321666140916120118</ArticleId><ArticleId IdType="pubmed">25245510</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollewe K, et al. ALSFRS-R score and its ratio: A useful predictor for ALS-progression. J. Neurol. Sci. 2008;275:69&#x2013;73. doi: 10.1016/j.jns.2008.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2008.07.016</ArticleId><ArticleId IdType="pubmed">18721928</ArticleId></ArticleIdList></Reference><Reference><Citation>Agus A, Planchais J, Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe. 2018;23:716&#x2013;724. doi: 10.1016/j.chom.2018.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2018.05.003</ArticleId><ArticleId IdType="pubmed">29902437</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarcz R, Burno JP, Muchowski PJ, Wu H-Q. Kynurenines in the mammalian brain: When physiology meets pathology. Nat. Rev. Neurosci. 2012;13:465&#x2013;477. doi: 10.1038/nrn3257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3257</ArticleId><ArticleId IdType="pmc">PMC3681811</ArticleId><ArticleId IdType="pubmed">22678511</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YK, Jeon SW. Neuroinflammation and the immune-kynurenine pathway in anxiety disorders. Curr. Neuropharmacol. 2018;16:574&#x2013;582. doi: 10.2174/1570159X15666170913110426.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X15666170913110426</ArticleId><ArticleId IdType="pmc">PMC5997870</ArticleId><ArticleId IdType="pubmed">28901278</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho HJ, et al. Sleep disturbance and kynurenine metabolism in depression. J. Psychosom. Res. 2017;99:1&#x2013;7. doi: 10.1016/j.jpsychores.2017.05.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychores.2017.05.016</ArticleId><ArticleId IdType="pmc">PMC5526094</ArticleId><ArticleId IdType="pubmed">28712413</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothhammer V, et al. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat. Med. 2016;22:586&#x2013;597. doi: 10.1038/nm.4106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4106</ArticleId><ArticleId IdType="pmc">PMC4899206</ArticleId><ArticleId IdType="pubmed">27158906</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, El Munsat TL. Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis Other Motor Neuron Disorders. 2009;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Labra J, Menon P, Byth K, Morrison S, Vucic S. Rate of disease progression: A prognostic biomarker in ALS. J. Neurol. Neurosurg. Psychiatry. 2016;87:628&#x2013;632. doi: 10.1136/jnnp-2015-310998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-310998</ArticleId><ArticleId IdType="pubmed">26152368</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CA, Want EJ, O'Maille G, Abagyan R, Siuzdak G. XCMS: Processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal. Chem. 2006;78:779&#x2013;787. doi: 10.1021/ac051437y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ac051437y</ArticleId><ArticleId IdType="pubmed">16448051</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>